The SULSA Assay Development Fund: accelerating translation of new biology from academia to pharma.
作者： Stuart P. McElroy , Philip S. Jones , Denise V. Barrault
DOI: 10.1016/J.DRUDIS.2016.09.028
关键词: Knowledge management 、 Financial management 、 Factory (object-oriented programming) 、 Quality (business) 、 Drug industry 、 Molecular targets 、 Bioinformatics 、 Project portfolio management 、 Academic community 、 Medicine 、 High-Throughput Screening Assays 、 Biology
摘要: With industry increasingly sourcing preclinical drug discovery projects from academia it is important that new academic discoveries are enabled through translation with HTS-ready assays. However, many scientifically interesting, novel molecular targets lack associated high-quality, robust assays suitable for hit finding and development. To bridge this gap, the Scottish Universities Life Sciences Alliance (SULSA) established a fund to develop meet quality criteria such as those of European Lead Factory. A diverse project portfolio was quickly assembled, review learnings successful outcomes showed highly cost-effective model leveraging significant follow-on resources, training early-career scientists establishing culture translational in community.
core.ac.uk
sci-hub.se 参考文章(10)
Jeremy R Everett, Academic drug discovery: current status and prospects Expert Opinion on Drug Discovery. ,vol. 10, pp. 937- 944 ,(2015) , 10.1517/17460441.2015.1059816
Emma Shanks, Robin Ketteler, Daniel Ebner, Academic drug discovery within the United Kingdom: a reassessment Nature Reviews Drug Discovery. ,vol. 14, pp. 510- 510 ,(2015) , 10.1038/NRD4661
Anna Karawajczyk, Fabrizio Giordanetto, Jorg Benningshof, Daniel Hamza, Tuomo Kalliokoski, Kees Pouwer, Remy Morgentin, Adam Nelson, Gerhard Müller, Alexander Piechot, Dimitrios Tzalis, Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective. Drug Discovery Today. ,vol. 20, pp. 1310- 1316 ,(2015) , 10.1016/J.DRUDIS.2015.09.009
Jérémy Besnard, Philip S. Jones, Andrew L. Hopkins, Andrew D. Pannifer, The Joint European Compound Library: boosting precompetitive research Drug Discovery Today. ,vol. 20, pp. 181- 186 ,(2015) , 10.1016/J.DRUDIS.2014.08.014
Jayme L. Dahlin, James Inglese, Michael A. Walters, Mitigating risk in academic preclinical drug discovery Nature Reviews Drug Discovery. ,vol. 14, pp. 279- 294 ,(2015) , 10.1038/NRD4578
Cathy Tralau-Stewart, Caroline M. R. Low, Nicola Marlin, UK academic drug discovery Nature Reviews Drug Discovery. ,vol. 13, pp. 15- 16 ,(2014) , 10.1038/NRD4200
Melvin Reichman, Peter B. Simpson, Open innovation in early drug discovery: roadmaps and roadblocks. Drug Discovery Today. ,vol. 21, pp. 779- 788 ,(2016) , 10.1016/J.DRUDIS.2015.12.008
Philip Jones, Stuart McElroy, Angus Morrison, Andrew Pannifer, The importance of triaging in determining the quality of output from high-throughput screening. Future Medicinal Chemistry. ,vol. 7, pp. 1847- 1852 ,(2015) , 10.4155/FMC.15.121
Guillaume Paillard, Philip Cochrane, Philip S. Jones, Willem P. van Hoorn, Andrei Caracoti, Herman van Vlijmen, Andrew D. Pannifer, The ELF Honest Data Broker: informatics enabling public-private collaboration in a precompetitive arena. Drug Discovery Today. ,vol. 21, pp. 97- 102 ,(2016) , 10.1016/J.DRUDIS.2015.11.005
Katie Kingwell, European Lead Factory hits its stride. Nature Reviews Drug Discovery. ,vol. 15, pp. 221- 222 ,(2016) , 10.1038/NRD.2016.64